Efficacy and safety of nivolumab in routine NSCLC treatment – an observational study in 5 lung cancer centers in Berlin, Germany
Daniel Misch(Helios Klinikum Emil von Behring), Annette Reinecke(Zentrum Überleben), Nikolaj Frost(Humboldt-Universität zu Berlin), Jens Kollmeier(Helios Klinikum Emil von Behring), Torsten Blum(MSB Medical School Berlin), Maike de Wit(Florida Hospital Cancer Institute), Christian Grohé(DRK Kliniken Berlin), Christian Grah(Gemeinschaftskrankenhaus Havelhöhe)
Cited by 2
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2023|605
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
|The Lancet Respiratory Medicine|2021|523
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
|Journal of Clinical Oncology|2023|386